Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneadetermined to play a key role in the formation of scar tissue.Connective tissue growth factor (CTGF) is a fibrogenic cytokine thatis a downstream mediator of many of the fibrotic actions of TGF- β.In this study, we determined the microRNAs (miRs) involved incorneal wound healing. We further examine the effect of miR-133bon the expression of CTGF, TGF-β, smooth muscle actin (SMA) andcollagen rabbit corneal fibroblast (RbCF).Methods: Laser ablated mouse corneas were collected at 0 and 2days post ablation. RNA was collected from the corneas and sampleswere analyzed using the mouse cell differentiation & developmentmiRNA PCR Array (QIAgen). The ability of miR-133b to target the3’ UTR of TGF-β and CTGF was tested using a luciferase assay inRbCF. PCR was used to determine the effect of miR-133b on CTGF,TGF-β, SMA and collagen in RbCF. Finally, a migration assay wasused to determine the effect of miR-133b on RbCF migration.Results: Two days after ablation, there were 37 out of 86 miRNAswith significant expression fold changes. Specifically, mir-133b hadthe greatest fold decrease at -14.33 and mir-22 had the greatest foldincrease of 7.16. The 3’UTR region of CTGF was targeted by premiR-133bas indicated by a significant decrease of 38% (p
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - CorneaTHE EFFECT OF LOCAL ROCK-INHIBITION ONCORNEAL SCARRING AFTER ALKALI BURN INJURYDavine Sijnave 1 , Karolien P. Hollanders 1 , Tine Van Bergen 1 , SarahVan de Velde 1 , Evelien Vandewalle 1 , Lieve K. Moons 2 , Dirk Leysen 3 ,Ingeborg Stalmans 1 . 1 Lab of Ophthalmology, KULeuven, Leuven,Belgium; 2 Department of Biology, KULeuven, Leuven, Belgium;3 Amakem Therapeutics, Diepenbeek, Belgium.Purpose: The aim of this study was to investigate the efficacy of alocal ROCK-inhibitor AMA0526 (Amakem NV) on corneal scarringinduced by alkali burn in an in vivo mouse model.Methods: Male Swiss mice (aged 6-8 weeks) were divided randomlyinto 3 groups after chemical cauterization of the cornea by alkali.Topical treatment was initiated after the injury and given once daily.The first group received 0.1% of the local ROCK-inhibitorAMA0526 versus Vehicle (experimental group 1), the second groupwas treated with bevacizumab (Avastin; anti-VEGF) versusAMA0526 (experimental group 2) and the third group was used ascontrol and received no treatment. Corneal opacity and cornealneovascularization were graded every other day according to a 0-4scoring. Blood vessel formation, collagen deposition and macrophagecorneal infiltration after injury were assessed and compared byimmunohistochemistry on day 7 and 14 after alkali burn.Results: Both corneal opacity and neovascularization were reducedafter AMA0526 treatment compared to the vehicle treated eye(p
Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10:
Page 13 and 14:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247: ARVO 2013 Annual Meeting Abstracts
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

Create successful ePaper yourself

Delete template?

Save as template?